Compugen Ltd. (CGEN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE 
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement
Compugen remains a 'Buy,' supported by pipeline progress, major pharma partnerships, and a cash runway extended into 2029. Key catalysts include the phase 3 MAIA-Ovarian cancer trial (COM701), with interim analysis expected in Q1 2027, and the anti-IL18BP antibody GS-0321 in phase 1. CGEN's non-dilutive deal with AstraZeneca monetizes rilvegostomig royalties, enhancing financial stability and preserving future upside.
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript
Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates
Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago.
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
Compugen is advancing its anti-PVRIG antibody COM701 in phase 1/2 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients, with interim data expected in 2H 2026. Positive proof-of-concept in platinum-resistant ovarian cancer and strong partnerships with AstraZeneca and Gilead provide multiple value-creation opportunities and financial stability. Upcoming catalysts include ESMO 2025 data releases for COM701 and AstraZeneca-partnered rilvegostomig in solid tumors, offering potential stock-moving events.
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Anat Cohen-Dayag - CEO, President & Director David Silberman - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Yvonne Naughton - Head of Investor Relations & Corporate Communications Conference Call Participants Leland James Gershell - Oppenheimer & Co. Inc., Research Division Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.02 per share a year ago.
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.
Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leerink Partners Leland Gershell - Oppenheimer Tony Butler - Rodman and Renshaw Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago.
